T 1930/14 (Antibody Purification/HOFFMANN-LA ROCHE) vom 28.11.2019
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2019:T193014.20191128
- Datum der Entscheidung
- 28. November 2019
- Aktenzeichen
- T 1930/14
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 06753791.0
- IPC-Klasse
- G01N 30/34C07K 16/00A61K 39/395C07K 1/18
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- Method for the purification of Antibodies
- Name des Antragstellers
- F. Hoffmann-La Roche AG
- Name des Einsprechenden
- Boehringer Ingelheim Pharma GmbH & Co. KG
MorphoSys AG
GE Healthcare Bio-Sciences AB
Teschner, Sabine
Strawman Limited
Huenges Martin c/o Maiwald Patentanwalts GmbH
Glaxo Group Limited - Kammer
- 3.3.04
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 123(2) (2007)European Patent Convention Art 54 (2007)European Patent Convention Art 56 (2007)European Patent Convention Art 83 (2007)European Patent Convention Art 84 (2007)Rules of procedure of the Boards of Appeal Art 12(2) (2007)Rules of procedure of the Boards of Appeal Art 12(4) (2007)Rules of procedure of the Boards of Appeal Art 13 (2007)
- Schlagwörter
- Novelty - main and auxiliary request 1 (no)
Auxiliary requests 2 and 4 to 6 - Admission (no)
Auxiliary request 3 - clarity (no)
Auxiliary request 7 - allowable (yes) - Orientierungssatz
- -
- Zitierende Akten
- T 0823/23
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent in amended form on the basis of the claims of auxiliary request 7 filed as auxiliary request 11 with the statement of grounds of appeal dated 2 December 2014, and a description and drawings to be adapted thereto, as necessary.
3. Respondent IV's request for a different apportionment of costs is rejected.